ReviewWorld journal of hepatology2023

Risk of hepatitis B reactivation in patients with myeloproliferative neoplasms treated with ruxolitinib.

Adeniyi Abraham Adesola et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.